All In MedTech

Device Trial Radar · NCT06654466

Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer

Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing

Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

100

Actual

Start

Feb 10, 2026

Primary completion

Mar 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Nest GenomicsNot on our public-company list
Sponsor type
Industry
Collaborators
Dana-Farber Cancer Institute; National Human Genome Research Institute (NHGRI)
First posted
Oct 23, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to see if a software platform can improve cancer screening in young adults with genetic risk for cancer. The trial will also help improve the software platform (Nest). The main questions it aims to answer are: * Do Nest users know more about their cancer risks and recommended care than non-users? * Do Nest users have less psychological distress than non-users? * Do Nest users share cancer risks with family and other doctors more than non-users? * Are Nest users more likely than non-users to have up-to-date care plans? Researchers will compare Nest users to non-users to see if the Nest users are more likely to do recommended cancer screening. Participants will: * Have a genetic counseling or follow up visit * Take a post-visit survey * Intervention arm only: use the Nest Patient Navigator * Complete screening and follow-up care recommended by doctors

Conditions

  • Hereditary Cancer Syndromes
  • Clinical Decision Support

Interventions

  • Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.Device

    The Nest software platform includes the Nest Care Studio, Nest Patient Navigator and the Analytics Dashboard. Nest Care Studio is a clinician facing portal that can be used standalone or electronic medical record (EMR) integrated. Care Studio enables clinicians to effectively manage patients' genetic information over time. Clinicians can see a list of patients that meet criteria for testing, run risk assessment calculations, order genetic tests, manage patients based on results and view education modules.The Nest Patient Navigator is a secure mobile device accessible platform that provides a centralized location for patients to store, manage, and follow-up with their genetic results. The Analytics Dashboard is an interactive dashboard that can track outcomes of genomic programs and trigger interventions to optimize them.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acceptability of Intervention Measure (AIM)Time frame: within 7 days of visit
  2. Gist Comprehension of Genetic Cancer RiskTime frame: Baseline, within 7 days of visit
  3. Knowledge of Cancer ScreeningTime frame: Baseline, within 7 days of visit

2 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dana Farber Cancer Institute

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.